Dublin, Ireland, 14th September 2016: DS Biopharma (DS) today announced the appointment of Dr. Markus Weissbach (MD, PhD) to Chief Operating Officer. Markus has been Medical Director of DS over the last year and will move to his new role with immediate effect.
Dr Markus Weissbach has more than 25 years working experience in the international pharmaceutical, biotech and CRO industry. His previous appointments include Chief Medical Officer Europe at Novartis Vaccines and Diagnostics; Executive Chairman, CEO and President of Averion International Corp; President of ICON Clinical Research Plc., Europe; Director Clinical Research and Development at Takeda Europe R&D and International Medical Clinical Director at Knoll AG. Dr. Weissbach has served as advisory/supervisory board member for companies such as CytoTools Biotech AG, Vasopharm, Cardiorentis, BernaBiotech, Sunesis and Otsuka. He has been instrumental in the successful NDAs and market launch of several NCEs and biologics in different indications. Dr. Weissbach has access to a vast personal network of KOLs in many therapeutic areas and has profound experience in dealing and negotiating with regulatory authorities in Europe and North America.
Commenting on the announcement, Dr. John Climax, DS Executive Chairman said ‘I am delighted to welcome Dr. Markus Weissbach into his new role within the DS team and I look forward to working with him in advancing the DS portfolio’.
About DS Biopharma
DS Biopharma, headquartered in Dublin, Ireland, is a privately held drug discovery and development company working on new medicines that improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. DS has developed a proprietary bioactive lipid technology platform. The Company is developing Topical DS107 for mild to moderate atopic dermatitis and Oral DS107 for moderate to severe atopic dermatitis. Both Topical and Oral DS107 are planned to begin separate Phase IIb clinical studies in Q.4 2016. In addition the Company expects to bring DS109, which is being explored as a treatment for inflammatory skin disorders, into the clinic later this year.
DS Biopharma: firstname.lastname@example.org, +35312933590